dc.contributor.author |
Raval, Vishal |
|
dc.contributor.author |
Karmakar, Jayashree |
|
dc.contributor.author |
Kannan, Kiruthika |
|
dc.contributor.author |
Oza, Sakshi |
|
dc.contributor.author |
Patil, Jagruti M. |
|
dc.contributor.author |
Mercado-Shekhar, Karla P. |
|
dc.coverage.spatial |
United Kingdom |
|
dc.date.accessioned |
2024-06-27T12:49:36Z |
|
dc.date.available |
2024-06-27T12:49:36Z |
|
dc.date.issued |
2024-06 |
|
dc.identifier.citation |
Raval, Vishal; Karmakar, Jayashree; Kannan, Kiruthika; Oza, Sakshi; Patil, Jagruti M. and Mercado-Shekhar, Karla P., "Ultrasound biomarkers: contrast-enhanced ultrasound and nakagami imaging to differentiate benign and malignant choroidal tumor", Current Eye Research, DOI: 10.1080/02713683.2024.2366307, Jun. 2024. |
|
dc.identifier.issn |
0271-3683 |
|
dc.identifier.issn |
1460-2202 |
|
dc.identifier.uri |
https://doi.org/10.1080/02713683.2024.2366307 |
|
dc.identifier.uri |
https://repository.iitgn.ac.in/handle/123456789/10172 |
|
dc.description.abstract |
Purpose
We hypothesized that contrast-enhanced ultrasound (CEUS) using a microbubble technique to quantify microvascular changes and Nakagami imaging for tissue characterization would provide a new approach for diagnosing and differentiating benign and malignant choroidal lesions.
Methods
Five patients with choroidal melanoma (CM) and five patients with choroidal hemangioma (CH) were selected. Definity®, which contains perflutren microbubbles, was administered as a slow IV bolus (1 ml). CEUS was performed for 1 min postinjection of the contrast agent with ultrasound radiofrequency data acquired from 10 s to 60 s. The contrast value was calculated for the whole tumor region. A gradient magnitude method was used for each postcontrast frames with 1-second interval, and the time-averaged value in pixel intensity gradient of postinjection frames was estimated and reported. Based on the Nakagami statistical distribution model, two Nakagami parameters, m and Ω, where m (shape parameter), representing tissue heterogeneity, and Ω (scale parameter), representing the average energy of backscattered signals, were studied.
Results
CEUS analysis showed that the time-averaged estimated contrast was significantly higher (p = 0.008) for CH compared to CM. Furthermore, the time-averaged contrast within the normal choroidal region was significantly higher than the choroidal tumor region for both CH and CM (p = 0.001 for CH cases and p < 0.0001 for CM cases). Nakagami analysis showed that the m estimates were significantly higher (p = 0.032) for CH (m = 0.61) than for CM (m = 0.28), indicating that CH is a more heterogeneous tumor than CM. The Ω estimates were significantly higher (p = 0.0019) for CH (Ω = 0.15) compared to CM (Ω = 0.03). These results may be due to the more vascular structures in CH compared to CM.
Conclusions
Quantitative intensity-based perfusion analysis using CEUS and backscattering tissue analysis using Nakagami imaging can provide valuable insights to differentiate benign and malignant choroidal lesions. |
|
dc.description.statementofresponsibility |
by Vishal Raval, Jayashree Karmakar, Kiruthika Kannan, Sakshi Oza, Jagruti M. Patil and Karla P. Mercado-Shekhar |
|
dc.language.iso |
en_US |
|
dc.publisher |
Taylor and Francis Group |
|
dc.subject |
Ultrasound biomarkers |
|
dc.subject |
Contrast-enhanced ultrasound |
|
dc.subject |
Nakagami imaging |
|
dc.subject |
Choroidal hemangioma |
|
dc.subject |
Choroidal melanoma |
|
dc.title |
Ultrasound biomarkers: contrast-enhanced ultrasound and nakagami imaging to differentiate benign and malignant choroidal tumor |
|
dc.type |
Article |
|
dc.relation.journal |
Current Eye Research |
|